European Chemicals Agency Provides Action Plan for Substance Evaluation
April 9, 2019
Beginning in February, the European Chemicals Agency (ECHA) adopted the updated community rolling action plan (CoRAP) for substance evaluation, which lists 100 substances to be evaluated between 2019-2021. For the 31 substances specified for 2019, the evaluating authorities have one year, beginning March 19, 2019, to carry out the evaluations.
The evaluation seeks to clarify whether additional information is required to conclude if a substance poses a risk to people or the environment. Substances are selected for evaluation based on concerns related to their suspected serious hazard properties, such as sensitization, persistence, bioaccumulation, acute toxicity, carcinogenicity, mutagenicity, or endocrine disruption, as well as their potential exposure to workers or consumers.
Each Member State will assess the suspected concern of each substance and initiate regulatory risk management actions, if necessary. Registrants are encouraged to keep their registrations up to date and to contact the evaluating Member State with questions or should additional information be required. The evaluating authorities will release their draft decisions, which will then be reviewed by the other Member States and the ECHA before issuing a final decision.
Please contact Nicholas Georges, Director, Scientific & International Affairs, at ngeorges@thehcpa.org for additional comments or questions.
Beginning in February, the European Chemicals Agency (ECHA) adopted the updated community rolling action plan (CoRAP) for substance evaluation, which lists 100 substances to be evaluated between 2019-2021. For the 31 substances specified for 2019, the evaluating authorities have one year, beginning March 19, 2019, to carry out the evaluations.
The evaluation seeks to clarify whether additional information is required to conclude if a substance poses a risk to people or the environment. Substances are selected for evaluation based on concerns related to their suspected serious hazard properties, such as sensitization, persistence, bioaccumulation, acute toxicity, carcinogenicity, mutagenicity, or endocrine disruption, as well as their potential exposure to workers or consumers.
Each Member State will assess the suspected concern of each substance and initiate regulatory risk management actions, if necessary. Registrants are encouraged to keep their registrations up to date and to contact the evaluating Member State with questions or should additional information be required. The evaluating authorities will release their draft decisions, which will then be reviewed by the other Member States and the ECHA before issuing a final decision.
Please contact Nicholas Georges, Director, Scientific & International Affairs, at ngeorges@thehcpa.org for additional comments or questions.